NEW YORK (GenomeWeb News) - Clinical Data's PGxHealth division has inked a sub-license agreement with Australia’s Victorian Clinical Genetics Services for a test that is aimed at diagnosing a deadly heart disorder.
Under the non-exclusive agreement, VCGS, a subsidiary of the Murdoch Children's Research Institute, will use the PGxHealth diagnostic to test for familial long QT syndrome in Australia and in New Zealand.
LQTS is an inherited disorder in heart rhythm that predisposes patients to sudden fainting spells, dizziness, palpitations, seizures, and sudden death.
According to PGxHealth, the test can help determine whether patients are at risk of LQTS, aid diagnosis of the syndrome, and possibly guide treatment options for those who have exhibited symptoms.
Financial terms of the agreement were not provided.